Abstract 5568
Background
Sarcoma patients, like many other patients with rare diseases, often experience a long diagnostic trajectory, which may negatively affect their outcome in many ways. So far, research on diagnostic intervals has been retrospective. Prospective studies with large patient numbers comparing diagnostic intervals in different health care systems have not been performed. Moreover, next to survival, health-related quality of life (HRQoL) and patient satisfaction can be affected by experiencing diagnostic delay. Currently, no data are available on how the diagnostic trajectory impacts patient-reported outcomes among sarcoma patients.
Trial design
A longitudinal cohort study, QUEST, will be conducted among newly diagnosed sarcoma patients 18 years and older in one of the participating study centers in The Netherlands (five centers) or United Kingdom (3 centers). Patients will be invited before start of treatment and asked to complete questionnaires on the diagnostic pathway, risk factors (demographic, geographic, tumour characteristics etc) and patient-reported outcomes (HRQoL, social functioning, psychological distress, care satisfaction) at diagnosis and 3, 6, 12 and 24 months later. Data collection will be done within PROFILES, an established international registry for cancer patient reported outcomes. Clinical data, including vital status and tumour characteristics, will be collected from patients’ records. We aim to include 530 patients within two years, recruitment started 01-02-2018, and up till now 300patients completed baseline questionnaires (219 in NL, response rate 60%; 66 in UK, response rate 45%). Descriptive statistics will be used to quantify diagnostic intervals. The association between diagnostic interval and HRQoL, stage at diagnosis, primary treatment and survival will be explored.
Clinical trial identification
Protocol Record 2017-3881.
Editorial acknowledgement
Legal entity responsible for the study
Winette van der Graaf.
Funding
Radboudumc PROFILES registry.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2935 - Correlation of progression free survival-2 and overall survival in solid tumors
Presenter: Paul Mainwaring
Session: Poster Display session 1
Resources:
Abstract
2273 - High performance of serial tumor biopsies in first in human (FIH) phase I trials.
Presenter: Jun Sato
Session: Poster Display session 1
Resources:
Abstract
5933 - Response rates and lesion-level progression patterns of solid tumor patients in an academic phase 1 program: implications for tumor heterogeneity
Presenter: Christopher Chen
Session: Poster Display session 1
Resources:
Abstract
3569 - Clinical Benefit and Response Rate in Early Phase Clinical Trials: First Report from a Single-Institution Study
Presenter: Antonio Marra
Session: Poster Display session 1
Resources:
Abstract
4139 - Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): a single Phase I Unit experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
4451 - Improving patient selection for immuno-oncology phase 1 trials: an external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O).
Presenter: Ghassan Al Darazi
Session: Poster Display session 1
Resources:
Abstract
1696 - Demonstrating the Changing Trends in Phase 1 Clinical Trials
Presenter: Christina Guo
Session: Poster Display session 1
Resources:
Abstract
3202 - Participation of Women in phase 1 oncology clinical trials
Presenter: Laura Vidal
Session: Poster Display session 1
Resources:
Abstract
4518 - Predictors for early trial discontinuation of patients with cancer participating in phase I clinical trials
Presenter: Joeri Douma
Session: Poster Display session 1
Resources:
Abstract
4368 - Safety of Tumor Treating Fields delivery to the torso: Meta analysis from TTFields clinical trials
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract